US Department of Health Report (2003). The State of the Art in
the Management of Osteoporosis.
NOF 2002. America’s Bone Health: The State of Osteoporosis and
Low Bone Mass in our Nation.
IOF Data (2003) www.osteofound.org.
Hanson DA et al. A specific immunoassay for monitoring bone
resorption: quantitation of type 1 collagen crosslinked
N-telopeptides in urine. J Bone Min Res 1992; 7:1251-1258
Apone, S., et al., (1994). J Bone Min Res 9 (suppl 1) pS178
Clemens JD et al. Evidence that serum NTx (collagentype I
N-telopeptides) can act as an immunochemical marker of bone
resorption. Clin Chem 1997; 43:2058-2063.
Eastell R et al. Biological variability of serum and urinary
N-telopeptides of type I collagen in postmenopausal women. J Bone
Miner Res 2000; 15: 594-598.
Ebeling, P.R (2001). In: Bone Markers: Biochemical and Clinical
Perspectives, (Eastell, Baumann, Hoyle, Wieczorek., Eds)., pp.
27-38. Martin Dunitz (Publ).
Schneider, D. L., et al., (1997) Arch Int Med 157: 1241-1245
Chesnut, CH et al., (1997) Am J Med 102:29-37
Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation
of treatment for osteoporosis. Am J Med. 2003;115:209-216.
Clowes JA, Peel NF, Eastell R. The impact of monitoring on
adherence and persistence with antiresorptive treatment for
postmenopausal osteoporosis: a randomized controlled trial. J Clin
Endocrinol Metab. 2004;89:1117-1123.
Greenspan SL et al. Early changes in biochemical markers of bone
turnover predict the long-term response to alendronate therapy in
representative elderly women: a randomized clinical trial. J Bone
Min Res. 1998; 13:1431-1438.
Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical
markers for prediction of 4-year response in bone mass during
bisphosphonate treatment for prevention of postmenopausal
osteoporosis. Bone. 2003;33:150-158.
Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD.
Relationship of early changes in bone resorption to the reduction
in fracture risk with risedronate. J Bone Miner Res.
2003;18:1051-1056.
Raisz, L. et al., (2000) Osteoporosis Int 11: 615-620
Sambrook, P. N. et al (2004) J Int Med 255: 503-511
Rosen CJ, et al. The predictive value of biochemical markers of
bone turnover for bone mineral density in early postmenopausal
women treated with hormone replacement or calcium supplementation.
J Clin Endocrinol Metab. 1997; 82:1904-1910.
Villareal, D. T. et al., (2001) JAMA. 286: 815-20
Garnero P, et al. Comparison of new biochemical markers of bone
turnover in late postmenopausal osteoporotic women in response to
alendronate treatment. J Clin Endocrinol Metab. 1994;
79:1693-1700.
Gertz BJ, et al. Monitoring bone resorption in early
postmenopausal women by an immunoassay for crosslinked collagen
peptides in urine. J Bone Miner Res. 1994; 9:135-142.
Gertz BJ, et al. Application of a new serum assay for type I
collagen cross-linked N-telopeptides: assessment of diurnal changes
in bone turnover with and without alendronate treatment. Calcif
Tissue Int. 1998; 63:102-106.
Scariano JK, et al. Serum levels of cross-linked N-telopeptides
and aminoterminal propeptides of type I collagen indicate low bone
mineral density in elderly women. Bone. 1998; 23:471-477.
Prestwood KM, et al. Low dose estrogen and calcium have an
additive effect on bone resorption in older women. J Clin
Endocrinol Metab. 1999; 84:179-183.
Miller, P. Clinical interpretation and utility of bone
densitometry. Osteoporosis: Diagnostic and therapeutic principles.
1996; 113-119
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The Use of
Biochemical Markers of Bone Turnover in Osteoporosis. Osteoporos
Int. 2000;11(Suppl 6):S2-S17.
Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with
once-weekly alendronate 70 mg compared with onceweekly risedronate
35 mg in women with postmenopausal osteoporosis: a randomized
double-blind study. J Bone Miner Res. 2005;20:141-151.
Delmas PD, Vrijens B, Cahall D, Le Moigne Amrani A, Grauer A,
Eastell R. What is the optimal level of bone turnover marker
supression with antiresorptive therapy? Evidence from the IMPACT
study. Osteoporos Int. 2005;16:S3.
Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med.
2005;353:487-497.
Recker, R., Gallagher, R., Amonkar, M. M., Smith, J., and
MacCosbe, P. Medication Persistence Is Better With Weekly
Bisphophonates, But It Remains Suboptimal. ASBMR 26th Annual
General Meeting. 2004.
Cramer, J. A., Amonkar, M. M., Hebborn, A., and Suppapanya, N.
Does Dosing Regimen Impact Persistence With Bisphosphonate Therapy
Among Postmenopausal Osteoporotic Women. ASBMR 26th Annual Meeting.
2004.
Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH, Gutierrez B.
Adherence and persistence associated with the pharmacologic
treatment of osteoporosis. Osteoporos Int. 2005;16 (Suppl
3):S24-S25.
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E.
Compliance with pharmacologic therapy for osteoporosis. Osteoporos
Int. 2003;14:965-968.
McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with
drug therapies for the treatment and prevention of osteoporosis.
Maturitas. 2004;48:271-287.
Sebaldt, R. J., Shane, E., Pham, B. Z., Cook, R. J., Thabane,
L., Petrie, A., Olszynski, W. P., Hanley, D. A., Brown, J., Adachi,
J. D., Murray, T., Josse, R., and Papaioannou, A. Impact of
Non-Compliance and Non- Persistence With Daily Bisphosphonates on
Longer-Term Effectiveness Outcomes In Patients With Osteoporosis.
ASBMR 26th Annual Meeting. 2004.
Siris, E., Rosen, C. J., Harris, S. T., Abbott, T. A., Barr, C.
E., and Silverman, S. Adherence to Bisphosphonate Therapy:
Relationship to Bone Fractures at 24 Months in Women with
Postmenopausal Osteoporosis. Sixth International Symposium on
Osteoporosis. 2005.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The
impact of compliance with osteoporosis therapy on fracture rates in
actual practice. Osteoporos Int. 2004;15:1003-1008.
IPSOS UK. The Adherence Gap: Why Osteoporosis Patients Don't
Continue With Treatment. IPSOS Health, European Survey of
Physicians and Women with Osteoporosis, January-April 2005.
2005.
Delmas PD, Vrijens B, Van de Langerijt L et al. Effect of
Reinforcement with Bone Turnover Marker Results on Persistence with
Risedronate Treatment in postmenopausal Women with Osteoporosis:
Improving the Measurements of Presistence on Actonel Treatment
(IMPACT) Study. Calcif Tissue Int. 2003;72:335.
Eastell R, Garnero P, Vrijens B et al. Influence of Patient
Compliance with Risedronate Therapy on Bone Turinover Marker and
Bone Mineral Density Response: The IMPACT Study. Calcif Tissue Int.
2003;72:408.